Neurotrophin-3-induced production of nerve growth factor is suppressed in Schwann cells exposed to high glucose: involvement of the polyol pathway.
Development of hypesthesia, a loss of sensitivity to stimulation, is associated with impaired regeneration of peripheral sensory fibers, in which Schwann cells play a key role by secreting nerve growth factor (NGF). Recent clinical trials indicated that an inhibitor of aldose reductase (AR), the rate-limiting enzyme in the polyol pathway, significantly improved hypesthesia in diabetic patients. The fact that AR is localized in Schwann cells led us to investigate the role of the polyol pathway in NGF production of isolated Schwann cells. Among various endogenous factors examined, increased production of NGF was demonstrated in the cells treated with neurotrophin-3 (NT-3) for 24 h. NT-3-induced NGF production was significantly suppressed when cells were cultured in the medium containing high glucose. In these cells, the levels of glutathione (GSH) and cAMP-response element binding protein (CREB) were reduced, whereas the level of activated nuclear factor-kappaB (NF-kappaB) was elevated. These changes were abolished when an AR inhibitor fidarestat was included in the medium. NT-3-induced NGF production was further attenuated in the cells treated with an inhibitor of GSH synthesis. Together, the enhanced polyol pathway activity under high-glucose conditions seems to elicit reduced NT-3-induced NGF production in Schwann cells. Enhanced oxidative stress linked to the polyol pathway activity may mediate this process.
Suzuki
Takeshi
T
Drug Development Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd, Mie, Japan. t_suszuki@mb4.skk-net.com
Sekido
Hiromi
H
Kato
Noriaki
N
Nakayama
Yukiharu
Y
Yabe-Nishimura
Chihiro
C
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000818:Animals; D001667:Binding, Competitive; D002478:Cells, Cultured; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005947:Glucose / Q000008:administration & dosage* / Q000494:pharmacology; D005978:Glutathione / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000378:metabolism; D020933:Neurotrophin 3 / Q000494:pharmacology*; D011108:Polymers / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D020812:Receptor, trkC / Q000378:metabolism; D012583:Schwann Cells / Q000187:drug effects* / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology
D017362:Cyclic AMP Response Element-Binding Protein; D004791:Enzyme Inhibitors; D016328:NF-kappa B; D020933:Neurotrophin 3; D011108:Polymers; C024617:polyol; D020932:Nerve Growth Factor; D000449:Aldehyde Reductase; D020812:Receptor, trkC; D005978:Glutathione; D005947:Glucose